Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)158.01
  • Today's Change2.01 / 1.29%
  • Shares traded1.89m
  • 1 Year change-31.17%
  • Beta-0.0779
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 18-Nov-24
Select bar for recommendation details.
Recommendations18-Nov-24
Buy9
Outperform13
Hold16
Sell0
Strong Sell0

Share price forecast in USD

The 30 analysts offering 12 month price targets for Biogen Inc have a median target of 250.00, with a high estimate of 342.00 and a low estimate of 180.00. The median estimate represents a 60.26% increase from the last price of 156.00.
High119.2%342.00
Med60.3%250.00
Low15.4%180.00

Earnings history & estimates in USD

On Oct 30, 2024, Biogen Inc reported 3rd quarter 2024 earnings of 4.08 per share. This result exceeded the 3.79 consensus of the 25 analysts covering the company and under-performed last year's 3rd quarter results by 6.42%.
The next earnings announcement is expected on Feb 11, 2025.
Average growth rate+2.01%
Biogen Inc reported annual 2023 earnings of 14.72 per share on Feb 13, 2024.
Average growth rate-16.83%
More ▼

Revenue history & estimates in USD

Biogen Inc. had 3rd quarter 2024 revenues of 2.47bn. This bettered the 2.43bn consensus of the 26 analysts covering the company. This was 0.12% above the prior year's 3rd quarter results.
Average growth rate-0.51%
Biogen Inc. had revenues for the full year 2023 of 9.84bn. This was 3.32% below the prior year's results.
Average growth rate-8.87%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.